Watch CNBC's full interview with Pfizer CEO Albert Bourla
9:31
$
CNBC
Watch CNBC's full interview with Pfizer CEO Albert Bourla
Pfizer CEO Albert Bourla joins 'Squawk on the Street' to discuss the company’s acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer’s strategy for clinical development and manufacturing.
2 days ago
Albert Bourla Interview
Watch CNBC's full interview with Pfizer CEO Albert Bourla on Covid vaccine rollout
20:02
$
Watch CNBC's full interview with Pfizer CEO Albert Bourla on Covid vaccine rollout
CNBC
Dec 14, 2020
Watch CNBC's full interview with Pfizer CEO Albert Bourla
9:53
$
Watch CNBC's full interview with Pfizer CEO Albert Bourla
CNBC
Jul 28, 2021
Watch CNBC’s full interview with Pfizer CEO Albert Bourla
9:29
$
Watch CNBC’s full interview with Pfizer CEO Albert Bourla
CNBC
May 3, 2022
Top videos
Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs
5:04
Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs
YouTubeCNBC Television
3.9K views2 days ago
Expect Pfizer bid to beat Novo for Metsera, says BMO's Evan David Seigerman
4:31
Expect Pfizer bid to beat Novo for Metsera, says BMO's Evan David Seigerman
YouTubeCNBC Television
2.5K views1 week ago
Pfizer Wins $10 Billion Bidding War For Obesity Drug Developer Metsera As Novo Nordisk Exits | 4K
9:37
Pfizer Wins $10 Billion Bidding War For Obesity Drug Developer Metsera As Novo Nordisk Exits | 4K
YouTubeCNN-News18
528 views4 days ago
Pfizer CEO Albert Bourla
Pfizer to buy Metsera in deal worth up to $10 billion
1:17
Pfizer to buy Metsera in deal worth up to $10 billion
YouTubeCNBC Television
445 views2 days ago
Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Metsera accepted a sweetened offer from Pfizer late on Friday, citing U.S. antitrust risks in Novo’s bid that it had previously called superior. Read more: cnb.cx/3WO8LQK | CNBC
1:17
Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Metsera accepted a sweetened offer from Pfizer late on Friday, citing U.S. antitrust risks in Novo’s bid that it had previously called superior. Read more: cnb.cx/3WO8LQK | CNBC
FacebookCNBC
1.3K views2 days ago
Pfizer After Covid: Time to Buy or Stay Away?
1:02
Pfizer After Covid: Time to Buy or Stay Away?
YouTubeFinance & Fries
12 hours ago